Bovine Mastitis Market Size & Share, by Type (Clinical Mastitis, Sub-Clinical Mastitis); Product (Antibiotics, Pain Killers, Vaccines); Route of Administration (Intra-mammary, Systemic); Therapy (Lactating Period, Dry Period); End-user (Veterinary Centers, Hospitals, Clinics, On-Site Treatment) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2033

  • Report ID: 4647
  • Published Date: Feb 27, 2023
  • Report Format: PDF, PPT

Companies Dominating the Bovine Mastitis Landscape

    • Boehringer Ingelheim International GmbH
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Zoetis Inc.
    • Merck & Co., Inc.
    • Ceva Santé Animale
    • Nimrod Veterinary Products Ltd
    • Bayer AG
    • ImmuCell Corporation
    • West Way Health
    • Neogen Corporation
    • Forte Healthcare Ltd.

Browse Key Market Insights with Data Illustration:


In The News

  • Boehringer Ingelheim International GmbH announced that the Clinical and Laboratory Standards Institute (CLSI) approved revised interpretive criteria for testing the susceptibility to Ubrolexin, an intramammary treatment for mastitis in lactating dairy cows that combines kanamycin and cefalexin.

  • Neogen Corporation announced a full range of dairy hygiene products, including teat dips and sprays, bulk tank cleaners, hoof care, and dairy cleaning products. Designed to reduce the transmission of mastitis-causing bacteria to dairy animals and provide high emollient content for teat protection and conditioning, the range of teat dips and sprays is suitable for pre-milking, pre/post-milking, and post-milking.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 4647
  • Published Date: Feb 27, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Enormous surge in dairy production across the globe, worldwide rise in the number of farm cattle, and globally escalating consumption of milk are some major factors driving the growth of the market.

The market is anticipated to attain a CAGR of 7% over the forecast period, i.e., 2023-2033.

Lack of awareness regarding bovine mastitis, growing use of antibiotic resistance pathogen, and inadequate accessibility of drugs are estimated to hamper the market growth.

The market in North America is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.

The major players in the market are Boehringer Ingelheim International GmbH, Zoetis Inc., Merck & Co., Inc., Ceva Santé Animale, Nimrod Veterinary Products Ltd, Bayer AG, ImmuCell Corporation, and others.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by type, product, route of administration, therapy, end-user, and by region.

The on-site treatment segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying